IL1A and amyloidosis: When only the FMF patients with or without amyloidosis were considered, in patients who received anti-IL-1 therapy, the fibrinogen level, RDW, and NLR, as well as inflammatory parameters such as ESR and CRP, were higher in patients who had amyloidosis than those who had not.